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Role of CDS9 in experimental glomerulonephritis in rats. CD59 is a
molecule which is present on the host cell membranes and inhibits
formation of membrane attack complex. A monoclonal antibody, 6D1,
recognizes a rat analogue of human CD59. 6D1 inhibits function of rat
CD59 and can enhance complement-mediated hemolysis in vitro. To
assess the role of CD59 in complement-mediated glomerular injury, 6Dl
was tested in a model of experimental glomerulonephritis induced by a
lectin and its antibodies. The left kidney of a rat was perfused either
with 200 sg of Lens culinaris hemoagglutinin (LCH) plus I mg of 6D1
(IgGl fraction) (Group I and III) or with LCH only (Group II) through
a cannula placed in the left renal artery. All the perfusate was discarded
from a cannula in the renal vein. The holes in the artery and vein were
repaired by microsurgery and the blood circulation was re-established.
Rats were injected either with 0.125 ml of rabbit anti-LCH serum
(Group I and II), or with normal rabbit serum (Group III) via tail vein
one minute after the recirculation. Fifteen minutes after injection,
significant C9 deposition in the glomeruli was observed only in Group I,
whereas C3 deposition in Group I and II were comparable. At Day 4,
total glomerular cells, proliferating cells, glomerular expression of
intercellular adhesion molecule-i and fibrin deposition in Group I were
all significantly increased when compared with Group II. At Day 7,
number of total glomerular cells and leukocytes in the glomeruli of
Group I were significantly higher than in Group II. The glomeruli in
Group III appeared normal throughout experiments. These data indi-
cate that the functional inhibition of a rat analogue of human CD59
worsens complement-mediated glomerular injury in vivo.
The membrane inhibitors of complement are a group of
proteins which inhibit complement activation at the C3 conver-
tase level or at the level of formation of the membrane attack
complex (MAC) [1, 2]. In humans a number of molecules have
been identified and shown to play protective roles against
homologous complement attack. Among these molecules,
CD59 [3], also known as 20 kDa homologous restriction factor
(HRF2O [4]), prevents the formation of MAC on the cell
membrane [5]. It has recently been shown that CD59 is essential
for the protection of nucleated cells against homologous com-
plement attack in vitro using cells in culture [6—8].
The kidney is an organ which is always under threat from
homologous complement attack. One can frequently see the
localization of immune deposits with complement components
in diseased kidneys [9]. It has been suggested that presence of
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high concentration of ammonium ions can activate the alterna-
tive pathway of complement and in certain circumstances leads
to tubulointerstitial injuries [10, 11]. Thus, the kidney may be
injured if there is no inhibitory system of complement activa-
tion. CD59 is expressed in the various structures of the normal
human kidney and it is hypothesized that renal CD59 plays a
protective role against homologous complement attack. Re-
cently, we reported a rat model of complement-mediated ex-
perimental glomerulonephritis which was initiated by the inter-
action of a lectin planted on the surface of glomerular
endothelial cells and its antibodies [12]. Using this model, the in
viva role of CD59 in the complement-mediated glomerular
injury was assessed using a neutralizing monoclonal antibody,
6D1, against rat CD59 [13]. The results obtained in the present
work showed that 6D 1 enhanced the deposition of rat C9 in the
glomeruli and worsened the subsequent glomerular injuries in
vivo. This is the first in vivo demonstration that CD59 plays
protective role in any tissue injury including complement me-
diated glomerular damage.
Methods
Animals
Female Wistar rats weighing about 275 grams were obtained
from Chubu Kagaku Shizai Co. Ltd. (Nagoya, Japan) and were
allowed free access to food and water.
Reagents
The characteristics of mouse monoclonal antibody 6D1 were
described previously [13]. Ascites made from 6Dl hybridoma
were obtained and IgG fraction was purified by protein A
affinity column chromatography (Pharmacia Fine Chemicals,
Uppsala, Sweden). Chromatographically purified LCH was
purchased from Sigma (St. Louis, Missouri, USA). Rabbit
anti-LCH serum was obtained as described previously [12].
Fluorescein-conjugated monoclonal anti-leukocyte common an-
tigen antibody (MRC OX-i) was purchased from Dainippon
Pharmaceutical Company (Osaka, Japan). Monoclonal anti-
body (lA29) against rat intercellular adhesion molecule 1
(ICAM-l) was a gift from Dr. M. Miyasaka (Tokyo Metropoli-
tan Institute for Clinical Medicine, Tokyo, Japan) [14]. Rabbit
anti-rat C9 was obtained according to the method described
before [15]. 1A29 and rabbit anti-rat C9 were labeled with biotin
according to a method described by Guesdon, Ternynck and
Abrameas [16]. Fluorescein-labeled goat antibodies against
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Table 1. Experimental protocol
Perfusion
LCH 6D1 iv. injection
Group I 200 jg I mg Rb anti-LCH (0.125 ml)
Group II 200 jig — Rb anti-LCH (0.125 ml)
Group III 200 g 1 mg NRS (0.125 ml)
Abbreviations are: rabbit anti-LCH, rabbit anti-LCH serum; NRS,
normal rabbit serum. Kidney specimens were examined 3 hours, 4 days
and 7 days after injection by histological and immunohistological
methods. Six rats in each group at the selected time point were
examined.
rabbit IgG, rat C3 and rat fibrin/fibrinogen were obtained from
Cappel Laboratories (Westchester, Pennsylvania, USA).
Kidney perfusion
To localize LCH and 6D 1 to the kidney but not to other
organs or blood cells in circulation, the isolated kidney perfu-
sion technique was used. The procedure of left kidney perfusion
was described in the previous paper [12, 17]. Under ether
anesthesia, the left kidney of a rat was exposed. Polyethylene
tubes were placed in the left renal artery and vein, and the
proximal portions of the vessels were temporarily ligated. The
left kidney was perfused at a rate of 2 mI/mm using a peristaltic
pump. Modified Tyrode buffer saturated with 95% oxygen and
5% carbon dioxide was used as a vehicle. All the perfusate was
discarded through a cannula placed in the renal vein. After
kidney perfusion, tubes were removed, and the holes in the
artery and vein were repaired by microsurgery. Blood circula-
tion of the left kidney was re-established by releasing the
ligature. The average time required for perfusion procedure was
about 10 minutes. In order to see the localization of 6D1 after
kidney perfusion, rats were perfused with 1 mg of 6D1 in 10 ml
of buffer with or without 200 jig of LCH according to the
procedure described above. Rats were sacrificed one minute
after recirculation of the kidney, and localization of mouse IgG
in the kidney was examined by immunofluorescence micros-
copy.
Experimental protocol
Rats were divided into three groups. Rats of group I were first
perfused with 200 jig of LCH and 1 mg of 6D1 in 10 ml of buffer
and then perfused with 2 ml of buffer to wash out the unbound
LCH and 6D1. One minute after recirculation of the left kidney,
0.125 ml of rabbit anti-LCH serum was injected via the tail vein.
Rats of Group II were perfused only with LCH and were
injected with the same amount of anti-LCH serum. The amount
of anti-LCH serum used in the present study was one-eighth of
that used in our previous study [12] to minimize the glomerular
injury. Rats of Group III were perfused as described for Group
I (LCH and 6D1) and were injected with 0.125 ml of normal
rabbit serum. Rats were sacrificed periodically at three hours,
four days or seven days after perfusion. The number of rats
studied in each group at the selected time point was 6. The
protocol is shown in Table 1. Since it is known from our
previous study that immune deposits are present on the surface
of glomerular endothelial cells 15 minutes after injection of
anti-LCH antibodies and they localize in the subendothelial
space but not on the endothelial surface three hours later, three
Fig. 1. Immunofluorescence micrograph showing the binding of 6D1
along glomerular capilla,y walls one minute after perfusion and recir-
culation. The left kidney of a rat was perfused with 6Dl. Binding of6Dl
was visualized by FITC-labeled rabbit anti-mouse IgG. (X400)
rats in each group were sacrificed 15 minutes after injection of
anti-LCH antibodies and glomerular deposition of rat C9 was
studied by immunofluorescence microscopy.
Histology and immunohistochemistry
At the time of sacrifice, the left kidneys were processed for
study by light, electron and immunofluorescence microscopy.
For light microscopic study, part of the kidney was fixed in
methacaln fixative [18] overnight and was embedded in paraffin.
Two jim thick sections were stained with periodic acid-Schiff
(PAS).
To detect proliferating cells, paraffin sections were stained
with a mouse monoclonal antibody (19A2, Coulter Immunol-
ogy, Hialeah, Florida, USA) against proliferating cell nuclear
antigen (PCNA) [19] according to a method described by
Garcia, Coltrera and Gown [20]. Sections were first deparaf-
finized and rehydrated. They were then incubated with 3%
hydrogen peroxide for 15 minutes, and incubated with 19A2 for
two hours. The sections were incubated with biotinylated goat
anti- mouse 1gM for one hour followed by incubation with
peroxidase-labeled streptoavidin (VECSTAIN ABC KIT, Vec-
tor, Burlingame, California, USA). The reaction was visualized
by incubating sections with diaminobenzidine tetrahydrochlo-
ride (Nakarai Chemicals, Osaka, Japan) and hydrogen perox-
ide.
For immunofluorescence microscopic study, small pieces of
kidney were snap frozen in liquid nitrogen and were kept at
—70°C until use. Two jim thick sections cut by a cryostat were
incubated with fluorescein-labeled rabbit antibodies against
mouse IgG and rat C3, and goat antibodies against rat fibrin and
rabbit IgG (Cappel, Westchester, Pennsylvania, USA). For the
detection of ICAM- 1, frozen sections were first treated with
Avidin D blocking solution (Vector Laboratories) for 15 min-
utes and then with biotin blocking solution (Vector Laborato-
ries) for 15 minutes at room temperature to minimize back-
ground staining. They were then incubated with biotinylated
1A29 (used at the concentration of 10 jig/mi) for 30 minutes at
room temperature. For the detection of glomerular C9, sections
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Fig. 2. Light micrographs (PAS staining).
Each micrograph shows a glomerulus from a
rat indicated as follows. (A) Group I at 3
hours; (B) Group II at 3 hours; (C) Group I at
4 days; (D) Group II at 4 days; (E) Group I at
7 days; (F) Group II at 7 days; (G) Group III
at 3 hours; (H) Group III at 7 days. (A
through H: x400)
were incubated with biotinylated anti-rat C9 (at the concentra-
tion of 20 g/ml) for 30 minutes at room temperature. All the
sections were then incubated with fluorescein-labeled avidin for
another 30 minutes. After final wash in PBS, all the sections
were mounted by cover glasses using p-phenylenediamine [21]
and were observed by Olympus epifluorescence microscopy
(Tokyo, Japan).
For electron microscopy, small pieces of kidney tissues were
fixed in 2% glutaraldehyde for two hours, and were osmicated.
They were then embedded in Epon 812 and ultrathin sections
were observed by a JEOL 100CX electron microscopy (Tokyo,
Japan).
Quantitation of data
The number of total glomerular cells was assessed by the
number of nuclei per equatorially cut glomerular cross section.
Similarly, the number of infiltrating cells was assessed by the
number of leukocyte common antigen positive cells, and that of
proliferating cells by the number of PCNA-positive cells in the
glomerular cross section. In each rat, 20 glomeruli were exam-
ined and the average number was calculated.
Glomerular ICAM-1 expression was assessed according to
distribution and intensity (Distribution Score and Intensity
Score). Distribution of ICAM-1 positive area in a glomerulus
was graded as 0 to 3 + according to the following criteria: 0,
negative; 1, positive in less than one-third of glomerular capil-
laries; 2, positive in one-third to two-thirds of glomerular
capillaries; 3, positive in more than two-thirds of glomerular
capillaries. The intensity of glomerular ICAM-1 expression was
graded from 0 (negative) to 3 (strongly positive). Glomerular
MAC deposition was assessed according to the staining inten-
sity for rat C9. Since part of proximal tubular basement
Fig. 3. Electron micrographs of the kidneys obtained at 3 hours. (A)
Group!; (B) Group II; (C) Group III. Symbols are: arrows, wrinkling of
GBM; arrowheads, swollen endothelium; and asterisks, platelets.
membranes of the control and nephritic rat kidneys were
strongly stained for C9 (Fig. 9), the staining intensity of this was
graded as 3. Staining intensity (0 negative to 3 strongly positive)
of each glomerulus was observed. Because significant number
of glomeruli of Group I and Group II rats showed very faint
staining for C9 (that is, staining is not negative but not so strong
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as 1), we assigned 0.5 to these glomeruli. As described above,
20 glomeruli were observed in each rat and the average grade
was calculated.
Glomerular fibrin deposition was observed both in the gb-
merular capillary lumen and along the glomerular capillary
walls. Fibrin deposition in the glomerular capillary lumen was
observed as a mass of positive area, while fibrin deposition
along glomerular capillary walls was observed as linear staining
along GBM. Fluorescein staining intensity was graded from 0
(negative) to 3 (strongly positive). The average grade was
similarly calculated in each rat.
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Fig. 4. Total glomerular cell count (A) and leukocyte infiltration (B).
Glomerular cell count is expressed as the number of nuclei per
glomerular cross section. The number of leukocytes in the glomerulus
was assessed by the number of leukocyte common antigen positive cells
in a glomerular cross section. Symbols are: (0) group 1; (0) Group II;() Group III.
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Fig. 5. Immunofluorescence micrographs
showing glomerularfibrin deposition and
ICAM-1 expression. Each photograph shows
immunostaining described as follows. (A)
Group I, fibrin, at 3 hours; (B) Group II,
fibrin, at 3 hours; (C) Group I, fibrin, at 4
days; (D) Group II, fibrin, 4 days; (E) Group
III, fibrin, at 4 days; (F) Group I, ICAM-l, at
4 days; (G) Group II, ICAM-l, 4 days; (H)
Group III, ICAM-l, 4 days. (A through H:
x400) Note that fibrin deposition is seen as
luminal mass in Group I and II rats at 3 hours
after induction of glomerular injury.
All the specimens were observed by two blinded persons.
Average number or grade was used for statistical analysis.
Urinary protein measurement
Rats were housed in metabolic cages overnight (16 hr) every
other day starting at the day of kidney perfusion. Urinary
protein was measured by a quantitative sulfosalicylic acid
method [221.
Statistical analysis
Statistical analysis was performed by Mann-Whitney U test.
Significant difference was set when the P value was less than
5% (or z value was more than 1.96) between two groups. All the
data are given in mean standard error.
Results
Binding of 6D1 following perfusion
6D 1 bound mainly to the glomerular capillary walls and
peritubular capillaries after perfusion (Fig. 1). Significant bind-
ing of 6D 1 was not clearly observed in the mesangial area when
studied by immunofluorescence microscopy 15 minutes after
kidney perfusion and reestablishment of blood flow in Group I
and III rats.
Histology and immunohistology
In Group I and II rats there was inifitration of platelets in the
glomerular capillary lumen, and the glomerular capillary walls
were wrinkled at three hours after initiation of glomerulonephri-
tis (Fig. 2A, B). At the ultrastructural level, vesiculation and
a)
8(0
C0
.0
0
Time after injection
Fig. 7. Glomerular deposition offibrin. Symbols are: (0) Group I; (0)
Group II. (A) Localization of fibrin in the glomerular capillary lumen.
(B) Localization of fibrin along glomerular capillary walls. Data of
Group III rats were omitted from the graphs because there was no fibrin
deposition at all.
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Fig. 6. Glomerular ICAM-1 expression. (A) shows distribution of gb-
merular ICAM-1 and (B) shows intensity.
swelling of endothelial cells were seen in Group I rats 15
minutes after initiation of nephtitis (not shown). There was
endothlial cell swelling, accumulation of platelets, and wrin-
kling of GBM in Group I and II rats at three hours (Fig. 3A, B).
Glomeruli of Group III rats showed noral appearance (Fig.
3C). At Day 4, segmental fibrin thrombi were observed and the
capillary lumen was further narrowed in Group I rats. There
was moderate hypercellularity seen at this stage in Group I and
II rats (Fig. 2C, D). At day 7, hypercellularity was more
prominent in Group I rats than in Group II rats (Fig. 2E, F).
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Rats of Group III showed no abnormality throughout the
experiments (Fig. 2G, H).
Immunofluorescence microscopic study showed strong dep-
osition of rabbit IgG and rat C3 along glomerular capillary walls
both in Group I and II rats at three hours alter initiation of
glomerulonephntis. Intensity of the staining for rabbit IgG and
rat C3 were comparable in these two groups. Mouse IgG was
detected along glomerular capillary walls in Group I and III rats
at this stage. Fluorescence intensity for mouse IgG was much
weaker than that for rabbit IgG. At Day 4, rabbit IgG and rat C3
were only faintly seen in the gloinerulus in Group I and II rats.
Mouse IgG was also very faintly seen in Group I and III but not
in Group II rats. At Day 7, glomeruli were negative for rabbit
IgG, rat C3 and mouse IgG. Immunofluorescence staining for
fibrin is described in the section below.
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Hypercellularity and cellular infiltration
The total number of glomerular cells, when assessed by the
number of nuclei per glomerular cross section, was significantly
increased in Group I and II rats at Day 4 and Day 7. Total
glomerular cell count was significantly higher in Group I rats
than in Group II at Day 4 and Day 7. Total glomerular cell count
remained at the normal level throughout the experiments in
Group III rats (Fig. 4A). The number of leukocytes infiltrating
into glomeruli was significantly higher in Group I and II rats
compared to Group III rats throughout the experiments. At Day
7, there were significantly more leukocytes observed in the
glomeruli in Group I rats than in Group II rats (Fig. 4B).
Glomerular ICAM-1 expression
Glomerular ICAM- 1 expression was almost identical at three
hours after perfusion in all groups, but the extent and intensity
of glomerular ICAM-! expression was significantly increased
by later time points in Group I rats. In contrast, glomerular
ICAM-l expression in Group II and III rats did not change
during the experiments (Figs. 5, 6).
Glomerular fibrin deposition
Fibrin deposition in the glomerular capillary lumen in Group
I and II rats was significantly higher at three hours than that in
Group III rats which showed no fibrin deposition. There was
still luminal fibrin deposition left in Group I rats at Day 4, while
there was very little deposition in Group II rats at this time.
Fibrin deposition along Glomerular capillary wall was observed
at Day 4 and Day 7 in Group I and II rats. At Day 4, fibrin
deposition was significantly stronger in Group I rats than in
Group II rats. At Day 7, fibrin deposition became comparable in
these two groups. Rats of Group III did not show any significant
fibrin deposition throughout the experiments (Figs. 5, 7).
Proliferating cells
PCNA positive cells were hardly detectable at three hours
and seven days after perfusion. At Day 4, the number of
proliferating cells in Group I and II rats was significantly
increased. Among these two groups, proliferation was more
prominent in Group I than in Group II (Fig. 8). In Group III
rats, there was no detectable proliferation.
Glomerular C9 deposition
Most of the glomeruli showed weak and finely granular
deposition of C9 in rats of Group I, while those of Group II and
Group III showed faint or negative staining for C9 (Fig. 9). The
staining intensity for C9 in the glomerulus was significantly
increased in Group I rats compared with the other two groups
(Fig. 10).
Proteinuria
There was no significant proteinuria in these three groups
throughout the experiments.
Discussion
In humans, CDS9 is present on the plasma membrane of cells
anchored by glycophosphatidyl inositol (GPI) and inhibits for-
mation of MAC on the cell membranes. CD59 molecule protects
host cells from indiscriminate attack by autologous complement
at the level of MAC formation, the final step of complement
activation. MAC, when formed on the non-nucleated cells like
erythrocytes, can induce immediate lysis of the cells. In con-
trast, MAC formed on the nucleated cells may induce various
effects on the function, metabolism and morphology of the cells
[23]. For example, MAC formed on the mesangial cell mem-
brane stimulates production of prostanoids/interleukin 1 [24]
and reactive oxygen metabolites [25]. In complement-mediated
glomerular injuries, formation of MAC on the glomerular cell
membrane might induce changes in function and metabolism
and affect the subsequent course of injury. Development of6Dl
[13], a mouse monoclonal antibody against the rat analogue of
human CD59 which enhances complement-mediated erythro-
cyte lysis and binds to rat glomeruli [26], enables us to assess
the role of CD59 in complement-mediated glomerular injuries in
vivo.
A model of experimental glomerulonephritis induced by LCH
and its antibodies is initiated by antigen-antibody interaction on
the surface of glomerular endothelial cells [12]. Based on the
observation by Johnson and his colleagues who were using a
similar model (concanavalin A and its antibodies), glonierular
injuries in this model are likely to be dependent on complement,
neutrophils and platelets [27]. Using this model, we investigated
the role of CD59 in complement-mediated glomerular injury by
neutralizing CD59 molecule in vivo. 6D1 was planted along the
glomerular capillary walls by kidney perfusion to inhibit the
function of CD59 in situ. Fifteen minutes after induction of
glomerulonephritis, glomerular deposition of C9 was signifi-
cantly increased in Group I than in other groups while glomer-
ular C3 deposition in Group I and II rats were comparable. This
finding suggests that C9 deposition was increased by the func-
tional inhibition of rat CD59 in vivo, and that formation of MAC
in the glomeruli of Group I rats was presumably enhanced. At
three hours after induction of glomerulonephritis, there was no
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Fig. 8. Proliferating cells. Symbols are: (0) Group 1; (0) Group II; (Li)
Group III. Degree of cell proliferation was assessed by the number of
PCNA-positive cells in the glomerular cross section. Significant in-
crease of PCNA-positive cells were observed in Group I and II rats only
at Day 4.
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Fig. 9. Immunofluorescence pictures showing
deposition of rat C9 and C3 in the glomerulus
15 minutes after injection of ant i-LCH (Group
I and II) or non-immune serum (Group HI).
(A) Group I, rat C9; (B) Group II, rat C9; (C)
Group III, rat C9; (D) Group I, rat C3; (E)
Group II, rat C3; (F) Group III, rat C3. (A
through F: x400) Note that C9 is strongly
positive in part of tubular basement
membranes in all rats, while it is weakly
positive in glomeruli only in Group I rats. (A)
The fluorescence intensity is grade 1.
significant difference with (Group I) or without (Group II)
presence of 6D1. However, at four days after induction of
glomerular injury there were significant differences in these two
groups. Fibrin deposition was prolonged and glomerular
ICAM-1 expression was enhanced in Group I rats. The mech-
anisms of this phenomenon might be explained by non-lethal
effects of MAC formed on nucleated cells. Neutralization of
CD59 by 6D 1 in the glomerular capillaries might have stimu-
lated the glomerular endothelial procoagulant activity through
the enhancement of MAC formation on the endothelial cell
surface. In favor of this view Hamilton et al, using human
umbilical vein endothelial cells in culture, reported that anti-
human CD59 antibody augmented the C5b-9-induced cellular
responses, including stimulated secretion of von Willebrand
factor and expression of the catalytic surface for the prothrom-
binase enzyme complex [281. Although there has been no report
showing evidence that MAC directly enhanced ICAM-1 expres-
sion, expression of glomerular ICAM-l in Group I rats might be
enhanced by the direct mediation of MAC formed on the
glomerular endothelial cells. There is a possibility that pro-
longed glomerular fibrin deposition and enhanced glomerular
ICAM-l expression could be mediated through the interaction
between the glomerular endothelial cells and the glomerular
infiltrating cells. It is well known that a series of cytokines
induce procoagulant activity and ICAM- 1 expression of endo-
thelial cells [29]. In the present study, however, fibrin deposi-
tion and ICAM-1 expression were significantly higher in Group
I rats at four days but not at three hours after initiation of
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Fig. 10. Deposition of rat C9 assessed by immunofluorescence staining
intensity 15 minutes after injection.
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expression of CD59 is regulated.
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